Naloxone hydrochloride intranasal - Nasus Pharma
Alternative Names: FMXIN-001; Naloxone microspheres powder - Nasus Pharma; Naloxone powder nasal spray - Nasus Pharma; NS-001Latest Information Update: 28 Feb 2024
At a glance
- Originator Nasus Pharma
- Class Antidotes; Behavioural disorder therapies; Benzofurans; Drug withdrawal therapies; Isoquinolines; Ketones; Laxatives; Morphinans; Small molecules
- Mechanism of Action Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Opioid-related disorders
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Opioid-related-disorders(In volunteers) in Canada (Intranasal, Powder)
- 11 Jan 2024 Chemical structure information added
- 10 Oct 2021 Nasus Pharma completes a Phase I trials in Opioid-related disorders (In volunteers) in Canada (Intranasal) (NCT04713709)